0 seconds of 1 minute, 55 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
01:55
01:55
 
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Pharmaxis (PXS) releases the final set of interim data from its phase two cancer trial, revealing “excellent” results
  • Ten patients with bone marrow cancer, myelofibrosis, completed six months of treatment with PXS-5505
  • Sixty per cent of patients showed “significant” improvement in the fibrosis grade in bone marrow biopsies
  • The treatment has been well tolerated, with no serious adverse events reported, and has promising signs of clinical efficacy
  • Shares are up 3.85 per cent, trading at 5.4 cents at 1:52 pm AEST

Pharmaxis (PXS) has released the final set of interim data from its phase two cancer trial, revealing “excellent” results.

Ten patients with bone marrow cancer, myelofibrosis, completed six months of treatment with PXS-5505, with 60 per cent of patients showing “significant” improvement in the fibrosis grade in bone marrow biopsies.

The phase two trial is designed to demonstrate PXS-5505, an inhibitor of all lysyl oxidase enzymes (LOX), as a safe and effective treatment in myelofibrosis patients who are intolerant, unresponsive, or ineligible for treatment with other approved drugs.

Patients under these conditions have limited treatment options with a life expectancy of around one year.

The treatment has been well tolerated, with no serious adverse events reported, and has promising signs of clinical efficacy.

The drug benefits include improved symptom scores, stable or improved hematological parameters, and reduced bone marrow fibrosis.

The original trial had 21 patients involved; however, 10 patients dropped out of the study due to a lack of clinical response or adverse events unrelated to the drug.

Later this year, final results from the trial will be submitted for presentation at the American Society of Haematology conference.

PXS shares were up 3.85 per cent, trading at 5.4 cents at 1:52 pm AEST.

PXS by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Aussie market weakens on disappointing bank earnings | Feb 19, 2025

The Aussie bourse did not have a great day on Wednesday, falling 0.83% after a selloff…

Hot Chili promises ‘a very large-scale porphyry is emerging’ in RIU Explorer’s address

Hot Chili Ltd continues to build on its shallow and high-grade porphyry discovery, La Verde, in…
Gareth Solley speaking at the RIU Explorer's Conference in WA

RIU Explorers Conference: From Black Cat’s first gold pour to a 200,000 ounce goal

WA Gold producer Black Cat Syndicate (ASX:BC8) has set the goal of producinig 200,000 ounces within…
The Market Online Video

ASX Market Update: Banking sector has another bad day as market pulls back from flat start | Feb 19, 2025

The Australian stock market weakened after a flattish start to Wednesday, with Finance again in the…